Cheng-Pu Sun

Cheng-Pu Sun

Auto-generated profile, based on publicly available information

Cheng-Pu Sun

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
TLTian‐Neng Li
Tian‐Neng Li
YWYi-Ju Wu
Yi-Ju Wu
HTHung-Wen Tsai
Hung-Wen Tsai
CSCheng‐Pu Sun
Cheng‐Pu Sun
YWYi-Hsuan Wu
Yi-Hsuan Wu
LWLily Hui-Ching Wang
Lily Hui-Ching Wang

7 February 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
CCChen-Yen Chung
Chen-Yen Chung
CSCheng-Pu Sun
Cheng-Pu Sun
MTMi-Hua Tao
Mi-Hua Tao
HWHui-Lin Wu
Hui-Lin Wu
SWSheng-Han Wang
Sheng-Han Wang
PCPei-Jer Chen
Pei-Jer Chen

9 September 2023 in Molecular Therapy
Verified
Journal Article
Open access
CSCheng-Pu Sun
Cheng-Pu Sun
CCChi-Wen Chiu
Chi-Wen Chiu
PWPing-Yi Wu
Ping-Yi Wu
STSzu-I Tsung
Szu-I Tsung
ILI-Jung Lee
I-Jung Lee
MTMi-Hua Tao
Mi-Hua Tao
The ongoing evolution of SARS-CoV-2, resulting in the emergence of new variants that are resistant to existing vaccines and therapeutic antibodies, has raised the need for novel strategies to combat the persistent global COVID-19 epidemic. In this study, a monoclonal anti-human angiotensin-converting enzyme 2 (hACE2) antibody, ch2H2, was isolated and humanized to block the viral receptor-binding domain (RBD) binding to hACE2, the major entry receptor of SARS-CoV-2. This antibody targets the RBD binding site on the N-terminus of hACE2 and has a high binding affinity to outcompete the RBD. In vitro, ch2H2 antibody showed potent inhibitory activity against multiple SARS-CoV-2 variants, including the most antigenically drifted and immune-evading variant Omicron. In vivo, adeno-associated virus (AAV)-mediated delivery enabled a sustained expression of mAb ch2H2, generating a high concentration of antibodies in mice. A single administration of AAV-delivered mAb ch2H2 significantly reduced viral RNA load and infectious virions and mitigated pulmonary pathological changes in mice challenged with SARS-CoV-2 Omicron BA.5 subvariant. Collectively, the results suggest that AAV-delivered hACE2-blocking antibody provides a promising approach for developing broad-spectrum antivirals against SARS-CoV-2 and potentially other hACE2-dependent pathogens that may emerge in the future.